Festinavir

Festinavir

Systematic (IUPAC) name
1-[(2R,5R)-5-ethynyl-5-(hydroxymethyl)-2H-furan-2-yl]-5-methylpyrimidine-2,4-dione
Clinical data
Pregnancy cat.	?
Legal status	Investigational
Identifiers
ATC code	None
PubChem	CID 3008897
ChemSpider	2278330
ChEMBL	CHEMBL124363
NIAID ChemDB	209894
Synonyms	4'-ethynylstavudine
Chemical data
Formula	C12H12N2O4
Mol. mass	248.235 g/mol
SMILES CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@](O2)(CO)C#C
InChI InChI=1S/C12H12N2O4/c1-3-12(7-15)5-4-9(18-12)14-6-8(2)10(16)13-11(14)17/h1,4-6,9,15H,7H2,2H3,(H,13,16,17)/t9-,12+/m1/s1 Key:OSYWBJSVKUFFSU-SKDRFNHKSA-N

Festinavir is an investigational new drug being developed by Bristol Myers-Squibb for the treatment of HIV infection. Festinavir is a nucleoside reverse transcriptase inhibitor that is active against HIV resistant to both abacavir and tenofovir, making the drug a candidate for people with multi-drug resistant (MDR) strains of the virus. Festinavir is a derivative of stavudine (d4T), but is less toxic.^{[citation needed]} It was originally developed at Yale University.